Evaluation of carbamazepine in epileptic patients

James Cereghino, J. T. Brock, B. G. White, J. K. Penry

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The efficacy, bioavailability and safety of carbamazepine when administered alone as an antiepileptic drug was evaluated in a double blind study of 45 institutionalized patients with uncontrolled seizures. During each of three 21 day treatment periods, 1/3 of the patients were assigned to receive either phenytoin (300 mg/day) phenobarbital (300 mg/day) or carbamazepine (1200 mg/day). 2 wk of regular medication (usual prestudy medication) separated each 21 day treatment period. Tablets containing carbamazepine (or placebo before phenytoin or phenobarbital treatment periods) were started 3 days before cessation of regular medication to provide a serum carbamazepine concentration at the time of cessation and to minimize transient side effects during initiation of carbamazepine therapy. Carbamazepine dosages during the 3 day period were 400, 800 and 1200 mg, respectively. Patients were returned to regular medication if they experienced excess seizures (defined as 4, or the equivalent of 4, tonic clonic seizures in an 8 hr period) during a treatment period. Analysis by a replicated Latin square model showed that the 3 drugs, when administered alone, were equal in their efficacy for control of seizures. During initiation of carbamazepine therapy, 26 of the 45 patients experienced malaise, visual disturbance, and difficulty with balance and performance of movement, without objective neurologic findings. These symptoms subsided within the first 5 days. The highest serum carbamazepine concentration measured was 13.7 mg/ml, with 70% of the values ranging from 5 to 10 mcg/ml.

Original languageEnglish (US)
Pages (from-to)433
Number of pages1
JournalNeurology
Volume23
StatePublished - 1973
Externally publishedYes

Fingerprint

Carbamazepine
Seizures
Phenytoin
Phenobarbital
Therapeutics
Neurologic Manifestations
Serum
Double-Blind Method
Anticonvulsants
Biological Availability
Tablets
Placebos
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Cereghino, J., Brock, J. T., White, B. G., & Penry, J. K. (1973). Evaluation of carbamazepine in epileptic patients. Neurology, 23, 433.

Evaluation of carbamazepine in epileptic patients. / Cereghino, James; Brock, J. T.; White, B. G.; Penry, J. K.

In: Neurology, Vol. 23, 1973, p. 433.

Research output: Contribution to journalArticle

Cereghino, J, Brock, JT, White, BG & Penry, JK 1973, 'Evaluation of carbamazepine in epileptic patients', Neurology, vol. 23, pp. 433.
Cereghino J, Brock JT, White BG, Penry JK. Evaluation of carbamazepine in epileptic patients. Neurology. 1973;23:433.
Cereghino, James ; Brock, J. T. ; White, B. G. ; Penry, J. K. / Evaluation of carbamazepine in epileptic patients. In: Neurology. 1973 ; Vol. 23. pp. 433.
@article{6f431759eba348589485b4320327b6ed,
title = "Evaluation of carbamazepine in epileptic patients",
abstract = "The efficacy, bioavailability and safety of carbamazepine when administered alone as an antiepileptic drug was evaluated in a double blind study of 45 institutionalized patients with uncontrolled seizures. During each of three 21 day treatment periods, 1/3 of the patients were assigned to receive either phenytoin (300 mg/day) phenobarbital (300 mg/day) or carbamazepine (1200 mg/day). 2 wk of regular medication (usual prestudy medication) separated each 21 day treatment period. Tablets containing carbamazepine (or placebo before phenytoin or phenobarbital treatment periods) were started 3 days before cessation of regular medication to provide a serum carbamazepine concentration at the time of cessation and to minimize transient side effects during initiation of carbamazepine therapy. Carbamazepine dosages during the 3 day period were 400, 800 and 1200 mg, respectively. Patients were returned to regular medication if they experienced excess seizures (defined as 4, or the equivalent of 4, tonic clonic seizures in an 8 hr period) during a treatment period. Analysis by a replicated Latin square model showed that the 3 drugs, when administered alone, were equal in their efficacy for control of seizures. During initiation of carbamazepine therapy, 26 of the 45 patients experienced malaise, visual disturbance, and difficulty with balance and performance of movement, without objective neurologic findings. These symptoms subsided within the first 5 days. The highest serum carbamazepine concentration measured was 13.7 mg/ml, with 70{\%} of the values ranging from 5 to 10 mcg/ml.",
author = "James Cereghino and Brock, {J. T.} and White, {B. G.} and Penry, {J. K.}",
year = "1973",
language = "English (US)",
volume = "23",
pages = "433",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Evaluation of carbamazepine in epileptic patients

AU - Cereghino, James

AU - Brock, J. T.

AU - White, B. G.

AU - Penry, J. K.

PY - 1973

Y1 - 1973

N2 - The efficacy, bioavailability and safety of carbamazepine when administered alone as an antiepileptic drug was evaluated in a double blind study of 45 institutionalized patients with uncontrolled seizures. During each of three 21 day treatment periods, 1/3 of the patients were assigned to receive either phenytoin (300 mg/day) phenobarbital (300 mg/day) or carbamazepine (1200 mg/day). 2 wk of regular medication (usual prestudy medication) separated each 21 day treatment period. Tablets containing carbamazepine (or placebo before phenytoin or phenobarbital treatment periods) were started 3 days before cessation of regular medication to provide a serum carbamazepine concentration at the time of cessation and to minimize transient side effects during initiation of carbamazepine therapy. Carbamazepine dosages during the 3 day period were 400, 800 and 1200 mg, respectively. Patients were returned to regular medication if they experienced excess seizures (defined as 4, or the equivalent of 4, tonic clonic seizures in an 8 hr period) during a treatment period. Analysis by a replicated Latin square model showed that the 3 drugs, when administered alone, were equal in their efficacy for control of seizures. During initiation of carbamazepine therapy, 26 of the 45 patients experienced malaise, visual disturbance, and difficulty with balance and performance of movement, without objective neurologic findings. These symptoms subsided within the first 5 days. The highest serum carbamazepine concentration measured was 13.7 mg/ml, with 70% of the values ranging from 5 to 10 mcg/ml.

AB - The efficacy, bioavailability and safety of carbamazepine when administered alone as an antiepileptic drug was evaluated in a double blind study of 45 institutionalized patients with uncontrolled seizures. During each of three 21 day treatment periods, 1/3 of the patients were assigned to receive either phenytoin (300 mg/day) phenobarbital (300 mg/day) or carbamazepine (1200 mg/day). 2 wk of regular medication (usual prestudy medication) separated each 21 day treatment period. Tablets containing carbamazepine (or placebo before phenytoin or phenobarbital treatment periods) were started 3 days before cessation of regular medication to provide a serum carbamazepine concentration at the time of cessation and to minimize transient side effects during initiation of carbamazepine therapy. Carbamazepine dosages during the 3 day period were 400, 800 and 1200 mg, respectively. Patients were returned to regular medication if they experienced excess seizures (defined as 4, or the equivalent of 4, tonic clonic seizures in an 8 hr period) during a treatment period. Analysis by a replicated Latin square model showed that the 3 drugs, when administered alone, were equal in their efficacy for control of seizures. During initiation of carbamazepine therapy, 26 of the 45 patients experienced malaise, visual disturbance, and difficulty with balance and performance of movement, without objective neurologic findings. These symptoms subsided within the first 5 days. The highest serum carbamazepine concentration measured was 13.7 mg/ml, with 70% of the values ranging from 5 to 10 mcg/ml.

UR - http://www.scopus.com/inward/record.url?scp=0015837006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015837006&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0015837006

VL - 23

SP - 433

JO - Neurology

JF - Neurology

SN - 0028-3878

ER -